Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)
NCT07135284 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-04-13
Summary
The purpose of this study is to collect data to assess the use of the LibAirty™ System for improving bronchiectasis symptoms and healthcare resource utilization when it is used at home.
The main question this study is trying to answer is: How often do adults with bronchiectasis experience pulmonary exacerbations (flare-ups of their lung condition) while using the LibAirty™ airway clearance system at home?
Participants will use the LibAirty™ airway clearance system at home as prescribed by their doctor - the device is not being provided as part of the study. The study will last for 12 months from the time participants begin using LibAirty.
During the study period, participants will continue with their usual clinic visits. At some of these regular visits (up to 4 times over the year), participants will be asked to complete short questionnaires about their bronchiectasis symptoms and their experience using LibAirty. At these same visits, the study team will also review participants' medical records and collect information related to their bronchiectasis condition, such as test results, medications, and any hospital or emergency room visits.
Conditions
- Bronchiectasis Adult
Interventions
- DEVICE
-
Airway clearance system
The device is prescribed as part of each participant's regular medical care, independently of the study. The study does not assign the device or alter standard treatment. Participants are observed while using the device as part of their usual care.
Sponsors & Collaborators
-
Synchrony-Medical, Ltd
lead INDUSTRY
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-20
- Primary Completion
- 2027-02-28
- Completion
- 2027-02-28
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
NCT06841640 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
NCT05495243 ·Status: COMPLETED ·Phase: PHASE2
-
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
NCT06731959 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
NCT00347659 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
NCT00769119 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
NCT01314716 ·Status: COMPLETED ·Phase: PHASE3
-
US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
NCT00515164 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
NCT01908933 ·Status: WITHDRAWN ·Phase: PHASE3
-
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
NCT00435253 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
NCT05865886 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
NCT02632851 ·Status: COMPLETED
-
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
NCT01449292 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung
NCT01225965 ·Status: COMPLETED ·Phase: NA
-
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
NCT05010577 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study
NCT00630227 ·Status: COMPLETED ·Phase: PHASE2
-
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
NCT01320566 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis
NCT02657473 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
NCT05654922 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
NCT01746095 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
NCT02950805 ·Status: COMPLETED ·Phase: PHASE1